Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure
**Background:** Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are risk factors for venous thromboembolism (VTE). Enoxaparin and unfractionated heparin (UFH) help prevent hospital-associated VTE, but few studies have compared them in COPD or HF. **Objectives:** To compare effec...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2024-02-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.92408 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860252873850880 |
|---|---|
| author | Alpesh N. Amin Alex Kartashov Wilson Ngai Kevin Steele Ning Rosenthal |
| author_facet | Alpesh N. Amin Alex Kartashov Wilson Ngai Kevin Steele Ning Rosenthal |
| author_sort | Alpesh N. Amin |
| collection | DOAJ |
| description | **Background:** Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are risk factors for venous thromboembolism (VTE). Enoxaparin and unfractionated heparin (UFH) help prevent hospital-associated VTE, but few studies have compared them in COPD or HF.
**Objectives:** To compare effectiveness, safety, and costs of enoxaparin vs UFH thromboprophylaxis in medical inpatients with COPD or HF.
**Methods:** This retrospective cohort study included adults with COPD or HF from the Premier PINC AI Healthcare Database. Included patients received prophylactic-dose enoxaparin or UFH during a >6-day index hospitalization (the first visit/admission that met selection criteria during the study period) between January 1, 2010, and September 30, 2016. Multivariable regression models assessed independent associations between exposures and outcomes. Hospital costs were adjusted to 2017 US dollars. Patients were followed 90 days postdischarge (readmission period).
**Results:** In the COPD cohort, 114 174 (69%) patients received enoxaparin and 51 011 (31%) received UFH. Among patients with COPD, enoxaparin recipients had 21%, 37%, and 10% lower odds of VTE, major bleeding, and in-hospital mortality during index admission, and 17% and 50% lower odds of major bleeding and heparin-induced thrombocytopenia (HIT) during the readmission period, compared with UFH recipients (all _P_ <.006). In the HF cohort, 58 488 (58%) patients received enoxaparin and 42 726 (42%) received UFH. Enoxaparin recipients had 24% and 10% lower odds of major bleeding and in-hospital mortality during index admission, and 13%, 11%, and 51% lower odds of VTE, major bleeding, and HIT during readmission (all _P_ <.04) compared with UFH recipients. Enoxaparin recipients also had significantly lower total hospital costs during index admission (mean reduction per patient: COPD, $1280; HF, $2677) and readmission (COPD, $379; HF, $1024). Among inpatients with COPD or HF, thromboprophylaxis with enoxaparin vs UFH was associated with significantly lower odds of bleeding, mortality, and HIT, and with lower hospital costs.
**Conclusions:** This study suggests that thromboprophylaxis with enoxaparin is associated with better outcomes and lower costs among medical inpatients with COPD or HF based on real-world evidence. Our findings underscore the importance of assessing clinical outcomes and side effects when evaluating cost-effectiveness. |
| format | Article |
| id | doaj-art-0abd6774d05a4098933c0cb07a4c19fd |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-0abd6774d05a4098933c0cb07a4c19fd2025-02-10T16:13:14ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362024-02-01111Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart FailureAlpesh N. AminAlex KartashovWilson NgaiKevin SteeleNing Rosenthal**Background:** Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are risk factors for venous thromboembolism (VTE). Enoxaparin and unfractionated heparin (UFH) help prevent hospital-associated VTE, but few studies have compared them in COPD or HF. **Objectives:** To compare effectiveness, safety, and costs of enoxaparin vs UFH thromboprophylaxis in medical inpatients with COPD or HF. **Methods:** This retrospective cohort study included adults with COPD or HF from the Premier PINC AI Healthcare Database. Included patients received prophylactic-dose enoxaparin or UFH during a >6-day index hospitalization (the first visit/admission that met selection criteria during the study period) between January 1, 2010, and September 30, 2016. Multivariable regression models assessed independent associations between exposures and outcomes. Hospital costs were adjusted to 2017 US dollars. Patients were followed 90 days postdischarge (readmission period). **Results:** In the COPD cohort, 114 174 (69%) patients received enoxaparin and 51 011 (31%) received UFH. Among patients with COPD, enoxaparin recipients had 21%, 37%, and 10% lower odds of VTE, major bleeding, and in-hospital mortality during index admission, and 17% and 50% lower odds of major bleeding and heparin-induced thrombocytopenia (HIT) during the readmission period, compared with UFH recipients (all _P_ <.006). In the HF cohort, 58 488 (58%) patients received enoxaparin and 42 726 (42%) received UFH. Enoxaparin recipients had 24% and 10% lower odds of major bleeding and in-hospital mortality during index admission, and 13%, 11%, and 51% lower odds of VTE, major bleeding, and HIT during readmission (all _P_ <.04) compared with UFH recipients. Enoxaparin recipients also had significantly lower total hospital costs during index admission (mean reduction per patient: COPD, $1280; HF, $2677) and readmission (COPD, $379; HF, $1024). Among inpatients with COPD or HF, thromboprophylaxis with enoxaparin vs UFH was associated with significantly lower odds of bleeding, mortality, and HIT, and with lower hospital costs. **Conclusions:** This study suggests that thromboprophylaxis with enoxaparin is associated with better outcomes and lower costs among medical inpatients with COPD or HF based on real-world evidence. Our findings underscore the importance of assessing clinical outcomes and side effects when evaluating cost-effectiveness.https://doi.org/10.36469/001c.92408 |
| spellingShingle | Alpesh N. Amin Alex Kartashov Wilson Ngai Kevin Steele Ning Rosenthal Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure Journal of Health Economics and Outcomes Research |
| title | Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure |
| title_full | Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure |
| title_fullStr | Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure |
| title_full_unstemmed | Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure |
| title_short | Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure |
| title_sort | effectiveness safety and costs of thromboprophylaxis with enoxaparin or unfractionated heparin among medical inpatients with chronic obstructive pulmonary disease or heart failure |
| url | https://doi.org/10.36469/001c.92408 |
| work_keys_str_mv | AT alpeshnamin effectivenesssafetyandcostsofthromboprophylaxiswithenoxaparinorunfractionatedheparinamongmedicalinpatientswithchronicobstructivepulmonarydiseaseorheartfailure AT alexkartashov effectivenesssafetyandcostsofthromboprophylaxiswithenoxaparinorunfractionatedheparinamongmedicalinpatientswithchronicobstructivepulmonarydiseaseorheartfailure AT wilsonngai effectivenesssafetyandcostsofthromboprophylaxiswithenoxaparinorunfractionatedheparinamongmedicalinpatientswithchronicobstructivepulmonarydiseaseorheartfailure AT kevinsteele effectivenesssafetyandcostsofthromboprophylaxiswithenoxaparinorunfractionatedheparinamongmedicalinpatientswithchronicobstructivepulmonarydiseaseorheartfailure AT ningrosenthal effectivenesssafetyandcostsofthromboprophylaxiswithenoxaparinorunfractionatedheparinamongmedicalinpatientswithchronicobstructivepulmonarydiseaseorheartfailure |